Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | SMO | Q99835 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9896032 | 1.00 | KDM2B (0.33) | KDM2BKDM4CCNR2LMNAHPGD | |
| SCHEMBL9896582 | 1.00 | KDM2B (0.33) | KDM2BKDM4CCNR2LMNAHPGD | |
| SCHEMBL9896033 | 1.00 | KDM2B (0.33) | KDM2BKDM4CCNR2LMNAHPGD | |
| SCHEMBL9897836 | 1.00 | KDM2B (0.33) | KDM2BKDM4CCNR2LMNAHPGD | |
| SCHEMBL9899390 | 1.00 | KDM2B (0.33) | KDM2BKDM4CCNR2LMNAHPGD | |
| SCHEMBL9897993 | 0.97 | KDM2B (0.33) | KDM2BKDM4CCNR2LMNAHPGD | |
| SCHEMBL9896413 | 0.97 | KDM2B (0.33) | KDM2BKDM4CCNR2LMNAHPGD | |
| SCHEMBL9895617 | 0.97 | KDM2B (0.33) | KDM2BKDM4CCNR2LMNAHPGD | |
| SCHEMBL9895616 | 0.97 | KDM2B (0.33) | KDM2BKDM4CCNR2LMNAHPGD | |
| SCHEMBL9897008 | 0.97 | KDM2B (0.33) | KDM2BKDM4CCNR2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927557-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | KDM2B 326/4885KDM4C 161/4885CNR2 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.